These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 34837230)

  • 1. Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019.
    Yu M; Wang DC; Li S; Lei YH; Wei J; Huang LY
    J Med Virol; 2022 Apr; 94(4):1513-1522. PubMed ID: 34837230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.
    Zhu Z; Lu Z; Xu T; Chen C; Yang G; Zha T; Lu J; Xue Y
    J Infect; 2020 Jul; 81(1):e21-e23. PubMed ID: 32283143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.
    Li Y; Xie Z; Lin W; Cai W; Wen C; Guan Y; Mo X; Wang J; Wang Y; Peng P; Chen X; Hong W; Xiao G; Liu J; Zhang L; Hu F; Li F; Zhang F; Deng X; Li L
    Med; 2020 Dec; 1(1):105-113.e4. PubMed ID: 32838353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.
    Wu L; Zheng Y; Liu J; Luo R; Wu D; Xu P; Wu D; Li X
    Aging (Albany NY); 2021 Apr; 13(8):10833-10852. PubMed ID: 33879634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis.
    Bhattacharyya A; Kumar S; Sarma P; Kaur H; Prajapat M; Shekhar N; Bansal S; Avti P; Hazarika M; Sharma S; Mahendru D; Prakash A; Medhi B
    Indian J Pharmacol; 2020; 52(4):313-323. PubMed ID: 33078733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The efficacy and safety of lopinavir/ritonavir and arbidol in patients with coronavirus disease 2019].
    Wen CY; Xie ZW; Li YP; Deng XL; Chen XT; Cao Y; Ou X; Lin WY; Li F; Cai WP; Li LH
    Zhonghua Nei Ke Za Zhi; 2020 Aug; 59(8):605-609. PubMed ID: 32388937
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical efficacy of methylprednisolone and the combined use of lopinavir/ritonavir with arbidol in treatment of coronavirus disease 2019.
    Xia Q; Dai W; Xu K; Ni Q; Li Y; Liu J; Zhao H; Guo Y; Yu L; Yi P; Su J; Lang G; Tao J; Shi D; Wu W; Wu X; Xu Y; Xu M; Yu L; Wang X; Cai H; Fang Q; Zhou J; Qiu Y; Li L
    J Med Virol; 2021 Jul; 93(7):4446-4453. PubMed ID: 33448426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.
    Lan X; Shao C; Zeng X; Wu Z; Xu Y
    Int J Clin Pharmacol Ther; 2021 May; 59(5):378-385. PubMed ID: 33624583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
    Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J
    J Infect; 2020 Jul; 81(1):e1-e5. PubMed ID: 32171872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
    Joseph BA; Dibas M; Evanson KW; Paranjape G; Vegivinti CTR; Selvan PT; Saravu K; Gupta N; Pulakurthi YS; Keesari PR; Varsha S; Chittajallu S; Dmytriw AA; Reierson NL; Mikoff N; Kamrowski S; Schmidt M; Davis AR; Pederson JM; Mishra HK; Touchette JC; Kallmes K
    Expert Rev Anti Infect Ther; 2021 Jun; 19(6):679-687. PubMed ID: 33187459
    [No Abstract]   [Full Text] [Related]  

  • 11. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
    Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.
    Qu J; Li GH; Wang JJ; He GF; Huang JJ; Chen Y; Qu Q; Chen XY; Lu Q
    Clin Exp Pharmacol Physiol; 2021 Feb; 48(2):203-210. PubMed ID: 33090501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.
    Wang Z; Chen X; Lu Y; Chen F; Zhang W
    Biosci Trends; 2020 Mar; 14(1):64-68. PubMed ID: 32037389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
    Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S
    CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial.
    Shi N; Guo L; Liu B; Bian Y; Chen R; Chen S; Chen Y; Chen Y; Cong X; Dong G; Guo J; Hu L; Jiang J; Leng L; Li B; Li D; Li H; Li J; Li L; Liu J; Lu C; Lv W; Miao Q; Qi W; Shi Z; Shi J; Shi H; Tian Y; Wang B; Wang G; Wang J; Wang W; Xian Y; Xie X; Xiong Y; Xu C; Xu M; Yan B; Yang J; Zhang L; Zhou Z; Zhu H; Huang L
    Phytomedicine; 2021 Jan; 81():153367. PubMed ID: 33260064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis.
    Wang M; Wu T; Zuo Z; You Y; Yang X; Pan L; Hu Y; Luo X; Jiang L; Xia Z; Deng M
    BMJ Support Palliat Care; 2021 Mar; 11(1):45-52. PubMed ID: 32958501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China.
    Guo YZ; Xu KJ; Li YT; Fu JD; Xu M; Yu L; Sheng JF; Zhu B
    J Zhejiang Univ Sci B; 2020 Dec.; 21(12):948-954. PubMed ID: 33843160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis.
    Amani B; Amani B; Zareei S; Zareei M
    Immun Inflamm Dis; 2021 Dec; 9(4):1197-1208. PubMed ID: 34347937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
    Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir.
    Brandariz-Nuñez D; Correas-Sanahuja M; Guarc E; Picón R; García B; Gil R
    Med Clin (Barc); 2020 Oct; 155(7):281-287. PubMed ID: 32718719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.